{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:16:04Z","timestamp":1790907364820,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>This phase 4, multicenter, open-label study was conducted to evaluate the safety, efficacy, and treatment satisfaction of switching to avatrombopag from another thrombopoietin receptor agonist (TPO-RA) in patients with immune thrombocytopenia (ITP). Adults who had received \u226590 days of treatment with eltrombopag or romiplostim and had a response (2 platelet counts [PCs] \u226550 \u00d7 109\/L) switched to avatrombopag with no protocol-defined washout period. The primary end point was the incidence of treatment-emergent adverse events (TEAEs) and serious TEAEs. Secondary end points were the proportion of patients who had a PC between \u226550 \u00d7 109\/L and \u2264200 \u00d7 109\/L (days 15, 30, 60, and 90) and change from baseline in each domain of the self-administered Treatment Satisfaction Questionnaire for Medication (TSQM) to day 90. Among 60 enrolled patients, 58.3% experienced TEAEs and 10.0% experienced serious TEAEs (1 related to avatrombopag [thrombocytopenia that resolved]; 5 unrelated [1 unrelated death]). A PC \u226550 \u00d7 109\/L to \u2264200 \u00d7 109\/L was reported for 51.7%, 31.7% (mean PC, 256.2 \u00d7 109\/L [standard deviation, 176.7 \u00d7 109\/L]), 55.0%, 60.0%, and 55.0% at baseline and on days 15, 30, 60, and 90, respectively. TSQM scores increased from baseline to day 90 across all domains (mean change: convenience, +13.5; effectiveness, +14.4; global satisfaction, +14.2; side effects, +8.3). There was no correlation between stable avatrombopag dose (day 90) and previous TPO-RA dose (high or low). Patients with ITP may safely switch from another TPO-RA to avatrombopag and maintain adequate PCs while experiencing improved treatment satisfaction. This trial was registered at www.ClinicalTrials.gov as #NCT04638829<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015635","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:04:00Z","timestamp":1742331840000},"page":"2733-2743","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-8176","authenticated-orcid":false,"given":"Michael D.","family":"Tarantino","sequence":"first","affiliation":[{"name":"1Bleeding and Clotting Disorders Institute, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailash","family":"Mosalpuria","sequence":"additional","affiliation":[{"name":"2Nebraska Hematology Oncology Cancer Center, Lincoln, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kolodny","sequence":"additional","affiliation":[{"name":"3Sobi, Inc, Morrisville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Sobi, Inc, Morrisville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vredenburg","sequence":"additional","affiliation":[{"name":"3Sobi, Inc, Morrisville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Jamieson","sequence":"additional","affiliation":[{"name":"3Sobi, Inc, Morrisville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"11","key":"2025061009165469300_bib1","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2025061009165469300_bib2","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2025061009165469300_bib3","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020;4(2):252]","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"2025061009165469300_bib4","unstructured":"NPLATE. Prescribing information. Amgen Inc 2008.. Accessed 14 September 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125268s163lbl.pdf."},{"key":"2025061009165469300_bib5","unstructured":"Nplate, INN (romiplostim). European Medicines Agency 2009.. Accessed 14 September 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nplate-epar-product-information_en.pdf."},{"key":"2025061009165469300_bib6","unstructured":"Promacta. Prescribing information. GlaxoSmithKline 2008. Accessed 14 September 2024. https:\/\/www.novartis.us\/sites\/www.novartis.us\/files\/promacta.pdf."},{"key":"2025061009165469300_bib7","unstructured":"Revolade, INN (eltrombopag) European Medicines Agency 2010.. Accessed 14 September 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revolade-epar-product-information_en.pdf."},{"key":"2025061009165469300_bib8","unstructured":"Doptelet. Prescribing information. Dova Pharmaceuticals Inc 2018.. Accessed 14 September 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210238s001lbl.pdf."},{"key":"2025061009165469300_bib9","unstructured":"Doptelet, INN (avatrombopag). European Medicines Agency 2019.. Accessed 14 September 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/doptelet-epar-product-information_en.pdf."},{"issue":"9610","key":"2025061009165469300_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"2025061009165469300_bib11","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"23","key":"2025061009165469300_bib12","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study [published correction appears in Blood. 2018;131(6):709]","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025061009165469300_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2025061009165469300_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09537104.2021.1881952","article-title":"Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension","volume":"33","author":"Al-Samkari","year":"2022","journal-title":"Platelets"},{"issue":"1","key":"2025061009165469300_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2022.10.005","article-title":"Patient-reported satisfaction, experiences, and preferences: same but different?","volume":"26","author":"M\u00fchlbacher","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"2025061009165469300_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/16078454.2023.2267942","article-title":"Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study)","volume":"28","author":"Jansen","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"2025061009165469300_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/16078454.2021.1978689","article-title":"Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study)","volume":"26","author":"McDonald","year":"2021","journal-title":"Hematology"},{"issue":"1","key":"2025061009165469300_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/16078454.2023.2253069","article-title":"Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort","volume":"28","author":"Lucchesi","year":"2023","journal-title":"Hematology"},{"key":"2025061009165469300_bib19","doi-asserted-by":"crossref","first-page":"2040620719837906","DOI":"10.1177\/2040620719837906","article-title":"Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia","volume":"10","author":"Gonz\u00e1lez-Porras","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2025061009165469300_bib20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/bjh.18081","article-title":"Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study","volume":"197","author":"Al-Samkari","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2025061009165469300_bib21","doi-asserted-by":"crossref","first-page":"100134","DOI":"10.1016\/j.rpth.2023.100134","article-title":"Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia","volume":"7","author":"Al-Samkari","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2025061009165469300_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"2025061009165469300_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2025061009165469300_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ejh.12932","article-title":"Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres","volume":"99","author":"Lakhwani","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025061009165469300_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/bjh.13266","article-title":"Use of eltrombopag after romiplostim in primary immune thrombocytopenia","volume":"169","author":"Gonz\u00e1lez-Porras","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2025061009165469300_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","article-title":"Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim","volume":"101","author":"Kuter","year":"2015","journal-title":"Int J Hematol"},{"issue":"6","key":"2025061009165469300_bib27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf","year":"2013","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2733\/2377239\/blooda_adv-2024-015635-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/11\/2733\/2377239\/blooda_adv-2024-015635-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T13:17:09Z","timestamp":1749561429000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/11\/2733\/536221\/Safety-efficacy-and-treatment-satisfaction-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,6,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015635","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,10]]},"published":{"date-parts":[[2025,5,30]]}}}